Abstract
Liposarcoma is the most common soft tissue sarcoma. With its various subtypes, the natural history of this disease can vary significantly from a locally recurrent tumor to a highly malignant one carrying a poor prognosis. Progress in the understanding of the specific molecular abnormalities in liposarcoma provides greater opportunity for new treatment modalities. Although surgical resection and radiation therapy remain the keystones for the management of primary liposarcoma, the inclusion of novel agents that target known abnormalities in advanced liposarcoma enhances the potential for improved outcomes.
Highlights
Liposarcoma represents the most common subtype of soft tissue sarcoma, comprising up to 20% of new diagnoses
Subtypes of liposarcoma Liposarcoma has a spectrum of pathological variations that directly impact prognosis
With respect to retroperitoneal liposarcoma Ecker et al performed a propensity score-matched cohort analysis of the US National Cancer Database and found that neoadjuvant radiation therapy led to an improvement in survival[46]
Summary
F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Any comments on the article can be found at the end of the article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
